Skip to main content
US EQUITIES PRE-MARKET CRYPTO 24/7
HALAL TRADING ROOM Sharia-screened signals
TERMINAL
DW

DWTXStock

Nasdaq Capital Market · Healthcare · US

$1.08 last close 2026-11-18
Open in terminalCompare
Price alert

Verdicts genuinely change. Free email alert the moment DWTX's does — no target price to set, unlike a price alert.

Sharia status
NOT YET SCREENED
Not screened yet — no methodology has been established for this symbol
0 of 3 pass our own screen — 4 of 7 could not be computed
🕌Open research, not a fatwa — verify with your own scholar.

Trade setup

Whether the technical picture shows an edge right now. Separate from the Sharia verdict, which this side never overrides.

SEPARATE FROM SHARIAH
No active setup right now. The technical picture doesn't show a clear edge — check back when the trend or momentum shifts.

Why this signal?

The factors behind the read, each shown with the figure it rests on, including the ones pointing the other way.

Structure0 of 5 timeframes bullish · 13.0% aligned
VWAPPrice below VWAP ($1.12)
VolumeRelative volume 5.5× the 20-day average
Momentum10-day rate of change +4.9%
Market & analysts
Wall Street consensus
BUY
8 analysts
Price target
$14.00
+1196.3% · 3 analysts
Institutional own.
10.6%
of shares
Momentum (10d)
+4.9%
rate of change
SMC grade
D · 38
13.0% aligned
100.00% *
Purification ratio (secondary provider, uncertain)
D · 38
SMC grade — 13.0% timeframe alignment
+4.9%
Rate of change (10d)
BUY
Wall Street consensus (8)
$14.00
Price target (+1196.3%) · 3 analysts
10.6%
Institutional ownership

🕌 In-house Compliance Research

Computed from published company financials, balance sheet as of 2026-09-30. These ratios come from the issuer's own published statements rather than structured SEC data.

AAOIFI divides by the market cap: $40.5M as of 2026-11-17.

Business activity: cleared (no excluded categories detected)

AAOIFI Unverified⚠️ a figure this standard divides by was not available, so it could not be scored — the rows below show what was and was not computed 2 of 2 ratios pass
RatioValueThresholdResult
Interest-bearing debt 0.29% 30.00% Pass(29.7pp buffer)
Interest-bearing investments 12.21% 30.00% Pass(17.8pp buffer)
Usmani Unverified⚠️ a figure this standard divides by was not available, so it could not be scored — the rows below show what was and was not computed 3 of 3 ratios pass
RatioValueThresholdResult
Interest-bearing debt 0.16% 33.00% Pass(32.8pp buffer)
Interest-bearing investments 6.54% 33.00% Pass(26.5pp buffer)
Non-liquid assets 93.46% at least 20.00% Pass(73.5pp above the floor)
MSCI Unverified⚠️ a figure this standard divides by was not available, so it could not be scored — the rows below show what was and was not computed 3 of 3 ratios pass
RatioValueThresholdResult
Interest-bearing debt 0.16% 33.33% Pass(33.2pp buffer)
Cash + interest-bearing securities 6.54% 33.33% Pass(26.8pp buffer)
Accounts receivable 6.54% 33.33% Pass(26.8pp buffer)
FTSE Unverified⚠️ a figure this standard divides by was not available, so it could not be scored — the rows below show what was and was not computed 3 of 3 ratios pass
RatioValueThresholdResult
Interest-bearing debt 0.00% 33.33% Pass(33.3pp buffer)
Cash + interest-bearing securities 6.54% 33.33% Pass(26.8pp buffer)
Accounts receivable 6.54% 50.00% Pass(43.5pp buffer)
Dow Jones Islamic Market Fail from an earlier screen 3 of 3 ratios pass

This Fail was decided by an earlier screen. The figures below are from the latest filing, which could not decide it on its own: non-permissible income not measured. The earlier verdict stands until a screen can decide it.

Scored against a trailing-average market cap (24-month), share-weighted by the issuer's own reported share counts — not today's market cap.

RatioValueThresholdResult
Interest-bearing debt 0.31% 33.00% Pass(32.7pp buffer)
Cash + interest-bearing securities 13.04% 33.00% Pass(20.0pp buffer)
Accounts receivable 0.00% 33.00% Pass(33.0pp buffer)
S&P Shariah Fail from an earlier screen 3 of 3 ratios pass

This Fail was decided by an earlier screen. The figures below are from the latest filing, which could not decide it on its own: non-permissible income not measured. The earlier verdict stands until a screen can decide it.

Scored against a trailing-average market cap (36-month), share-weighted by the issuer's own reported share counts — not today's market cap.

RatioValueThresholdResult
Interest-bearing debt 0.42% 33.00% Pass(32.6pp buffer)
Cash + interest-bearing securities 17.59% 49.00% Pass(31.4pp buffer)
Accounts receivable 0.00% 49.00% Pass(49.0pp buffer)
MSCI M-Series Fail from an earlier screen 3 of 3 ratios pass

This Fail was decided by an earlier screen. The figures below are from the latest filing, which could not decide it on its own: non-permissible income not measured. The earlier verdict stands until a screen can decide it.

Scored against a trailing-average market cap (36-month), share-weighted by the issuer's own reported share counts — not today's market cap.

RatioValueThresholdResult
Interest-bearing debt 0.42% 33.33% Pass(32.9pp buffer)
Cash + interest-bearing securities 17.59% 33.33% Pass(15.7pp buffer)
Accounts receivable 17.59% 49.00% Pass(31.4pp buffer)

Research only, not investment advice. Thresholds are each standard-setter's published limits; a ratio marked “at least” is a floor, not a ceiling.

The numbers the ratios are built from

Read from DWTX's own filings. Every percentage on this page is one of these lines divided by another, so the inputs are shown rather than asserted.

LineFigureAs reportedRead from
RevenueTotal revenue for the period not measured — —
Interest-bearing debtShort and long-term borrowings $0 2026-09-30 no debt tag reported in 3+ years (treated as $0)
Cash and interest-bearing securitiesCash, equivalents and marketable securities $4.9M 2026-09-30 CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
Total assetsBalance sheet total $75.6M 2026-09-30 Assets
Market capDenominator for AAOIFI $40.5M live quote price x shares
36-month average market capDenominator for S&P Shariah and MSCI M-Series $19.8M 756 trading days closes x shares
24-month average market capDenominator for Dow Jones Islamic Market $26.1M 504 trading days closes x shares
Non-permissible revenueInterest and excluded income $0 2026-09-30 no interest-income tag reported in 3+ years (treated as $0)

Two dates, not one: a balance-sheet line and an income-statement line cover different windows by design, so each figure carries its own.

Sources

Filing information. Balance sheet as of 2026-09-30. Income statement as of 2026-09-30. Screened 2026-11-17.

Filing links appear after the next screen: this row was screened before filing citations were recorded.

  • Total assets$75.6M
    Assets · balance sheet as of 2026-09-30
  • Interest-bearing debt$0
    no debt tag reported in 3+ years (treated as $0) · balance sheet as of 2026-09-30
  • Cash and interest-bearing securities$4.9M
    CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents · balance sheet as of 2026-09-30
  • Receivables$0
    no receivables tag reported in 3+ years (treated as $0) · balance sheet as of 2026-09-30
  • Interest income (non-permissible)$0
    no interest-income tag reported in 3+ years (treated as $0) · income statement as of 2026-09-30
  • Market cap$40.5M
    Market-data quote at screen time, 2026-11-17 · not a filing figure, so no link

What changed, and when

Verdict history for DWTX. A verdict that never moved is recorded too, so a quiet history reads as measured rather than missing.

  • 2026-09-07 No change recorded No verdict change for DWTX has been recorded since tracking began. The scan ledger records that the compliance detectors ran, not which symbols each pass covered.

Tracked since 2026-09-07.

Shariah-compliant alternatives

Compliant companies in Biotechnology listed on the same market, largest first. Each is screened on its own; none carries a documented concern or a hold.

CompanyMarket capPrice, day
VRTXVertex Pharmaceuticals, Inc. $121.1B —
REGNRegeneron Pharmaceuticals, Inc. $85.3B —
ARGXArgen X SE - ADR $64.3B —
ONCBeOne Medicines Ltd. American Depositary Shares $40.4B —
ALNYAlnylam Pharmaceuticals Inc $31.6B —

A dash means no fresh quote is cached for that symbol; this list does not fetch one.

Tracked investors holding DWTX
InvestorFirmPositionWeightAs of
Israel Englander Millennium Management $1M 0.0% 2026-09-30
Ken Griffin Citadel Advisors $0M 0.0% 2026-09-30

From the most recent 13F on file. A 13F reports long US equity positions quarterly and in arrears — it is what a manager held on the report date, not what they hold today.

6.825.373.932.481.032025-11-192026-05-212026-11-18

Pinch or scroll to zoom · drag to pan — both axes move · double-click to reset

Support & Resistance
S3
0.85
S2
0.95
S1
1.01
PIVOT
1.11
R1
1.17
R2
1.27
R3
1.33

Classic floor-trader pivots from the last completed daily bar. Highlighted pills are the levels bracketing the current price.

Price Forecast

The range is measured volatility (ATR over the horizon), not a target — a wider band means a more volatile asset, not a stronger view. The direction is the indicator tally below. Every forecast is recorded when made and scored against the real price when it comes due, including the wrong ones. Not a recommendation, and not a fatwa.

7-day expected range
0.6402 – 1.52
±40.72% from 1.08, made 2026-11-18 · resolves 2026-11-25
STRONG SELL
from 19 indicators
78.7% of our last 25417 forecasts — across every instrument we forecast, not just this one — landed inside their stated range, and 53.4% called the direction correctly.

Technical Summary

Standard indicator thresholds (RSI 30/70, Stochastic 20/80, CCI ±100, Williams %R −80/−20, MACD histogram sign, price vs. average) computed on daily bars. A summary of what common indicators say — not a recommendation, and not this site's own trading verdict.

STRONG SELL
19 indicators
OscillatorsSTRONG BUY
3 buy · 4 neutral · 0 sell
Moving averagesSTRONG SELL
0 buy · 0 neutral · 12 sell
Every indicator, and what it reads
IndicatorValueSignal
RSI (14)40.00NEUTRAL
Stochastic %K (14)38.17NEUTRAL
CCI (20)-58.05NEUTRAL
Williams %R (14)-61.83NEUTRAL
MACD (12,26,9)0.01BUY
ROC (10)4.85BUY
Momentum (10)0.05BUY
EMA (10)1.12SELL
SMA (10)1.14SELL
EMA (20)1.17SELL
SMA (20)1.15SELL
EMA (30)1.23SELL
SMA (30)1.19SELL
EMA (50)1.34SELL
SMA (50)1.34SELL
EMA (100)1.59SELL
SMA (100)1.60SELL
EMA (200)2.15SELL
SMA (200)1.86SELL

About DWTX

Healthcare · Biotechnology

Dogwood Therapeutics, Inc., a development-stage biotechnology company, focuses on the development of medicine to treat pain and fatigue-related disorders. Its lead product candidates include IMC-1, a combination of famciclovir and celecoxib that has completed Phase 2b clinical trial to treat fibromyalgia; Halneuron, which is in Phase 2b clinical trial for the treatment of chemotherapy-induced neuropathic pain and cancer pain, as well as pre-clinical trial for acute surgical pain; and IMC-2, a combination of valacyclovir and celecoxib intended to synergistically suppress herpesvirus activation; and Serpin Peptide 16 that is in early Phase 1 development to reduce neuropathy secondary to treat chemotherapeutic agents that are neurotoxic. The company was formerly known as Virios Therapeutics, Inc. and changed its name to Dogwood Therapeutics, Inc. in October 2024. The company was founded in 2012 and is based in Alpharetta, Georgia.

dwtx.com ↗

Background via Yahoo Finance — informational, not part of the verdict.

Grade verdict

Weak — low conviction, small size or skip

SMC — Top Down

Market structure by timeframe, read from real bars. A bias per timeframe rather than a forecast — timeframes disagreeing is information, not noise.

TimeframeBiasBars
📅 Daily RANGING 43
⏰ 4H RANGING 21
🕐 1H RANGING 85
⏱ 15-Min BEARISH 130
⏲ 5-Min BEARISH 234

Momentum & Volume

Rate of change and relative volume against this symbol's own recent history. Momentum describes what price has done; it is not a claim about what it will do.

+4.9%
Rate of change (10d)
5.5×
Volume vs its 20-day average
-0.07
MACD (no fresh cross)

Peer Movement

How the rest of the sector moved over the same window. Context for a price move, never a cause of one.

Peer movement computing — it will appear here on its own.

Before you act on this

The questions worth asking about any verdict on this page, answered plainly.

Is this a fatwa?

No. HTR applies published screening standards to a company's own filings and shows the result under each one. It is research, not a religious ruling. For a ruling that applies to you, ask a qualified scholar.

Why can the standards disagree?

Because they measure different things. Some divide interest-bearing debt by market cap, others by total assets, and the thresholds differ too. The same filing can clear one line and cross another. HTR shows every verdict rather than averaging them into one label.

How often is this re-screened?

Ratios are recomputed when a new filing lands, and the whole watchlist is re-screened on a rolling basis. The date on the verdict above is the last time this symbol was actually recomputed, not the last time the page was built.

Do I need to purify dividends?

If a company earns some non-permissible income, many scholars hold that the same share of any dividend should be given away. The non-permissible income figure above is the number that calculation starts from — the purification calculator finishes it, showing the filing figures behind the ratio and both the proportional and the AAOIFI per-share convention.

Open research, not a fatwa. HTR applies published screening standards to filings and publishes what they say, including when they disagree. Nothing here is financial advice or a recommendation to buy or sell. Verdicts can change when new filings land.

Compare with

Same screen, different answers. Comparison is where the standards disagreeing becomes useful rather than confusing.

Peer screening computing — it will appear here on its own.

Insider Activity (90d)

Insider transactions reported in the last ninety days. Insiders sell for reasons that have nothing to do with a view, so a sale on its own is not a signal.

NO DATA   0 buys · 0 sells

COT Positioning — E-MINI S&P 500 - CHICAGO MERCANTILE EXCHANGE

The weekly CFTC Commitments of Traders report for the broad market it tracks, not for this symbol. Positioning context for the tape — it says nothing about this company.

NEUTRAL   report date 2026-11-10 · Asset managers net 914130 (-14454)

AI Summary

Plain-language summary of the evidence already on this page — the Sharia screen, structure, momentum, and order flow above. It explains the read; it doesn't make the call. Generated on demand (a live AI call), never run automatically.